UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia

Oncogene, 2021-02, Vol.40 (7), p.1217-1230

2021

Volltextzugriff (PDF)

Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

Proceedings of the National Academy of Sciences - PNAS, 2010-04, Vol.107 (16), p.7461-7466

2010

Volltextzugriff (PDF)

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

Molecular cancer therapeutics, 2019-07, Vol.18 (7), p.1205-1216

2019

Volltextzugriff (PDF)

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728

Cancer science, 2020-06, Vol.111 (6), p.2123-2131

2020

Volltextzugriff (PDF)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours

British journal of cancer, 2020-03, Vol.122 (5), p.658-667

2020

Volltextzugriff (PDF)

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways

Cancer science, 2019-12, Vol.110 (12), p.3802-3810

2019

Volltextzugriff (PDF)

Author Correction: Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy

Scientific reports, 2024-02, Vol.14 (1), p.4784-4784, Article 4784

2024

Volltextzugriff (PDF)

Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors

Journal of medicinal chemistry, 2021-03, Vol.64 (5), p.2669-2677

2021

Volltextzugriff (PDF)

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells

Cancer science, 2021-01, Vol.112 (1), p.422-432

2021

Volltextzugriff (PDF)

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy

Scientific reports, 2023-05, Vol.13 (1), p.8821-8821, Article 8821

2023

Volltextzugriff (PDF)

Genome editing of Nf1, Pten, and Trp53 in neonatal mice induces glioblastomas positive for oligodendrocyte lineage transcription factor 2

Journal of Toxicologic Pathology, 2021, Vol.34(4), pp.359-365

2021

Volltextzugriff (PDF)

Functionally distinct Gata3/Chd4 complexes coordinately establish T helper 2 (Th2) cell identity

Proceedings of the National Academy of Sciences - PNAS, 2013-03, Vol.110 (12), p.4691-4696

2013

Volltextzugriff (PDF)

Pharmacologic dissection of the overlapping impact of heat shock protein family members on platelet function

Journal of thrombosis and haemostasis, 2020-05, Vol.18 (5), p.1197-1209

2020

Volltextzugriff (PDF)

First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2546-2546

2017

Volltextzugriff (PDF)

Temperature dependence of optical constants for InSb films including molten phases

Applied physics letters, 2008-01, Vol.92 (1)

2008

Volltextzugriff (PDF)

Excess HDM2 Impacts Cell Cycle and Apoptosis and Has a Selective Effect on p53-dependent Transcription

The Journal of biological chemistry, 2006-06, Vol.281 (25), p.16943-16950

2006

Volltextzugriff (PDF)

Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors

Future oncology (London, England), 2024-03, Vol.20 (9), p.507-519

2024

Volltextzugriff (PDF)

Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial

European journal of cancer (1990), 2019-11, Vol.121, p.29-39

2019

Volltextzugriff (PDF)

Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.531-551

2019

Volltextzugriff (PDF)

Abstract P06-02: Discovery of TAS0953/HM06, a novel next generation RET-specific inhibitor capable of inhibiting RET solvent front mutations

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P06-P06-02

2021

Volltextzugriff (PDF)

hCAS/CSE1L Associates with Chromatin and Regulates Expression of Select p53 Target Genes

Cell, 2007-08, Vol.130 (4), p.638-650

2007

Volltextzugriff (PDF)

TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models

Molecular cancer therapeutics, 2015-01, Vol.14 (1), p.14-22

2015

Volltextzugriff (PDF)

A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity

Cancer science, 2005-09, Vol.96 (9), p.614-619

2005

Volltextzugriff (PDF)

Characterization of cell line with dedifferentiated GIST‐like features established from cecal GIST of familial GIST model mice

Pathology international, 2023-05, Vol.73 (5), p.181-187

2023

Volltextzugriff (PDF)

TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models

Molecular cancer therapeutics, 2024-02, Vol.23 (2), p.174-186

2024

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(100)

Publikationsform

Sprache

Englisch
(102)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia

Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways

Author Correction: Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy

Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy

Genome editing of Nf1, Pten, and Trp53 in neonatal mice induces glioblastomas positive for oligodendrocyte lineage transcription factor 2

Functionally distinct Gata3/Chd4 complexes coordinately establish T helper 2 (Th2) cell identity

Pharmacologic dissection of the overlapping impact of heat shock protein family members on platelet function

First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors

Temperature dependence of optical constants for InSb films including molten phases

Excess HDM2 Impacts Cell Cycle and Apoptosis and Has a Selective Effect on p53-dependent Transcription

Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors

Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial

Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor

Abstract P06-02: Discovery of TAS0953/HM06, a novel next generation RET-specific inhibitor capable of inhibiting RET solvent front mutations

hCAS/CSE1L Associates with Chromatin and Regulates Expression of Select p53 Target Genes

TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models

A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity

Characterization of cell line with dedifferentiated GIST‐like features established from cecal GIST of familial GIST model mice

TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models

Suchergebnisse filtern